These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 8532697

  • 1. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
    Dabbs DJ.
    Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697
    [Abstract] [Full Text] [Related]

  • 2. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ.
    Anticancer Res; 1996 Aug; 16(5B):3141-7. PubMed ID: 8920782
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, Agnantis NJ.
    Anticancer Res; 2000 Aug; 20(6B):4221-5. PubMed ID: 11205251
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E, Kamina S, Demou A, Kontostolis M, Lolis D, Agnantis NJ.
    Anticancer Res; 1999 Aug; 19(3A):2133-9. PubMed ID: 10470161
    [Abstract] [Full Text] [Related]

  • 5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA, Marberger M.
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [Abstract] [Full Text] [Related]

  • 6. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
    Gasparini G, Pozza F, Meli S, Reitano M, Santini G, Bevilacqua P.
    Anticancer Res; 1991 May; 11(6):2015-21. PubMed ID: 1776834
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of biomarkers in breast and prostate cancer.
    Grizzle WE, Myers RB, Arnold MM, Srivastava S.
    J Cell Biochem Suppl; 1994 May; 19():259-66. PubMed ID: 7823598
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: comparison with histopathological parameter.
    Hasebe T, Mukai K, Yamaguchi N, Ishihara K, Kaneko A, Takasaki Y, Shimosato Y.
    Mod Pathol; 1994 Jan; 7(1):37-43. PubMed ID: 7909154
    [Abstract] [Full Text] [Related]

  • 18. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE, Pollice AA, Smith CA, Janocko LE, Sweeney L, Brown KA, Singh SG, Gu L, Yakulis R, Lucke JF.
    Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
    [Abstract] [Full Text] [Related]

  • 19. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C, Henrique R, Monteiro P, Lopes C, Bento MJ, De Sousa CP, Lopes P, Olson S, Silva MD, Page DL.
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [Abstract] [Full Text] [Related]

  • 20. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F, Núñez MJ, Piqueras V, Lucas AR, Sánchez J, Tejerina A, Schneider J.
    Anticancer Res; 2002 May; 22(1A):295-8. PubMed ID: 12017306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.